Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2025
The REgistry of Flow and Perfusion Imaging for Artificial Intelligence with positron emission tomography (REFINE PET):Rationale and design.
СтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ramirez Giselle, Lemley Mark, Shanbhag Aakash, Kwiecinski Jacek, Miller Robert J H, Kavanagh Paul B, Liang Joanna X, Dey Damini, Slipczuk Leandro, Travin Mark I, Alexanderson Erick, Carvajal-Juarez Isabel, Packard René R S, Al-Mallah Mouaz, Einstein Andrew J, Feher Attila, Acampa Wanda, Knight Stacey, Le Viet T, Mason Steve, Sanghani Rupa, Wopperer Samuel, Chareonthaitawee Panithaya, Buechel Ronny R, Rosamond Thomas L, deKemp Robert A, Berman Daniel S, Di Carli Marcelo F, Slomka Piotr J
Аннотация
BACKGROUND: The REgistry of Flow and Perfusion Imaging for Artificial Intelligence with positron emission tomography (REFINE PET) was established to collect multicenter PET and associated computed tomography (CT) images, together with clinical data and outcomes, into a comprehensive research resource. REFINE-PET will enable validation and development of both standard and novel cardiac PET/CT processing methods.
METHODS: REFINE-PET is a multicenter, international registry that contains both clinical and imaging data. The PET scans were processed using QPET software (Cedars-Sinai Medical Center, Los Angeles, CA), while the CT scans were processed using deep learning (DL) to detect coronary artery calcium (CAC). Patients were followed up for the occurrence of major adverse cardiovascular events (MACE), which include death, myocardial infarction, unstable angina, and late revascularization (>90 days from PET).
RESULTS: The REFINE-PET registry currently contains data for 35595 patients from 14 sites, with additional patient data and sites anticipated. Comprehensive clinical data (including demographics, medical history, and stress test results) were integrated with more than 2100 imaging variables across 34 categories. The registry is poised to address a broad range of clinical questions, supported by correlating invasive angiography (within 6 months of PET myocardial perfusion imaging [MPI]) in 5955 patients and a total of 9278 major adverse cardiovascular events during a median follow-up of 4.2 years.
CONCLUSIONS: The REFINE-PET registry leverages the integration of clinical, multimodality imaging, and novel quantitative and AI tools to advance the role of PET/CT MPI in diagnosis and risk stratification.
METHODS: REFINE-PET is a multicenter, international registry that contains both clinical and imaging data. The PET scans were processed using QPET software (Cedars-Sinai Medical Center, Los Angeles, CA), while the CT scans were processed using deep learning (DL) to detect coronary artery calcium (CAC). Patients were followed up for the occurrence of major adverse cardiovascular events (MACE), which include death, myocardial infarction, unstable angina, and late revascularization (>90 days from PET).
RESULTS: The REFINE-PET registry currently contains data for 35595 patients from 14 sites, with additional patient data and sites anticipated. Comprehensive clinical data (including demographics, medical history, and stress test results) were integrated with more than 2100 imaging variables across 34 categories. The registry is poised to address a broad range of clinical questions, supported by correlating invasive angiography (within 6 months of PET myocardial perfusion imaging [MPI]) in 5955 patients and a total of 9278 major adverse cardiovascular events during a median follow-up of 4.2 years.
CONCLUSIONS: The REFINE-PET registry leverages the integration of clinical, multimodality imaging, and novel quantitative and AI tools to advance the role of PET/CT MPI in diagnosis and risk stratification.